INTRODUCTION AND OBJECTIVES:
In August 2014, the Movember Foundation launched the GAP3 initiative, which covers the largest centralized prostate cancer (PCa) active surveillance (AS) database to date. Its primary goal is to create a global consensus on the selection and monitoring of men with low risk PCa. Ultimately, worldwide uniform guidelines will be developed.
METHODS: The global database was created by combining patient data from established AS cohorts worldwide. The database contains information on clinical and demographic characteristics at time of PCa diagnosis for all men included in the GAP3 cohort, their clinical follow-up, including information on discontinuation of AS and potential following treatments. Descriptive analyses were performed by a team of statisticians from the five Movember regions around the world (the USA, Canada, Australasia, the UK and Europe).
RESULTS: The GAP3 database illustrates variability in inclusion criteria and follow-up on 14,024 patients from 25 centers (Figure 1 ). At time of diagnosis, median age was 65 yr (IQR 60-70); median PSA was 5.4 ng/ml (IQR 4.0-7.3); median PSA density was 0.12 ng/ml (IQR 0.09-0.17); and median prostate volume was 44 cc (IQR 33-59). Most men had a clinical stage T1 (71%), a biopsy Gleason score of 6 (87%), one tumor-positive biopsy core (61%) and no comorbidity (64%). Men on AS had a median follow-up time of 2.4 years (IQR 1.1-4.7 years). Maximum follow-up time was 21.3 years. After 5, 10 and 15 years of follow-up, respectively, 57%, 37% and 22% of men were still on AS; 23%, 30% and 35% discontinued due to protocol-based progression (Figure 2) . CONCLUSIONS: GAP3 is the largest worldwide data effort to date integrating patient data from men with PCa on AS protocols. The results of GAP3 will allow individual patients and clinicians to have greater confidence in the personalized decision to either delay or proceed with active treatment.
Source of Funding:
The Movember Foundation.
PD28-06 VARIATION IN THE USE OF ACTIVE SURVEILLANCE FOR LOW-RISK PROSTATE CANCER
INTRODUCTION AND OBJECTIVES: To assess utilization of active surveillance in men with low-risk prostate cancer at Commission on Cancer designated facilities and to evaluate the influence of institutional factors associated with receipt of active surveillance.
METHODS: Retrospective cohort of 40,215 men within the National Cancer Data Base, with low-risk prostate cancer, as defined by National Comprehensive Cancer Network guidelines, diagnosed between 2012 and 2013. Multivariable and mixed-effects models were used to examine variation and factors associated with active surveillance.
RESULTS: Between 2012 and 2013 the overall rate of active surveillance was 14%. Unadjusted proportion of patients eligible for active surveillance ranged from 0% to 100%. The adjusted probability of active surveillance receipt by institution varied from 0% to 53%. Mean adjusted probability of receiving active surveillance was 0.033 (95% confidence interval [CI] 0.023-0.256). Relative to patients treated at Comprehensive Community Cancer Centers patients treated at Community Cancer Programs and academic institutions had higher odds of receiving active surveillance (odds ratio [OR] 2.74, 95% CI 1. p<0.001 and OR 2.50 95%, p<0.001, respectively) . Relative to patients treated at very low volume facilities, patients treated at very-high volume facilities had higher odds of receiving active surveillance (OR 3.50, 95%CI 1.84-6.68; p<0.001). Patient and hospitallevel variables accounted for 41% of the overall variation, whereas the treating institution accounted for 35% of the unexplained variability.
CONCLUSIONS: The overall use of active surveillance at Commission on Cancer designated facilities remains low at 14%. Significant variation in the use of active surveillance was seen across facilities with patients treated at academic and very high volume centers being more likely to receive active surveillance. A non-negligible proportion of the variation is explained by the treating institution. Given the Vol. 197, No. 4S, Supplement, Saturday, May 13, 2017 THE JOURNAL OF UROLOGY â e519
